Treatment of Chorea Associated with Huntington Disease
Protocol: STUDY00005677
Full Title
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington Disease
This study is to evaluate the long-term safety and tolerability of daily valbenazine (20, 40, 60, or 80mg) for the treatment of chorea associated with Huntington's Disease (HD) for up to 104 weeks. This study will enroll approximately 120 medically stable male and female subjects with HD who previously completed study drug dosing during the maintenance period as well as the study visit at Week 14 for Study NBI-98854-HD3005.
Compensation: Yes
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
To participate in this study, subjects must meet the following criteria:
1. Participated in Study NBI-98854-HD3005 and
a) Study drug dosing completion of Study NBI-98854-HD3005, as demonstrated by completed study drug dosing during the dose maintenance period as well as the study visit at Week 14.
b) Early terminated Study NBI-98854-HD3005 for administrative reasons due to COVID-19 (eg, site closure related to COVID-19).
2. Subject has provided a Research Advance Directive; only applicable for subjects who have the capacity to consent at the time of informed consent signing.
3. Subject, or his/her LAR, has voluntarily provided informed consent and has signed an ICF and is willing and able to adhere to the study regimen and study procedures described in the ICF.
4. Subjects who are consented through a LAR must agree to have a reliable caregiver in attendance at all study visits.
Age Group: Adults
Principal Investigator: Kelly Andrzejewski
Tia Warrick
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact